Skip to Content

  • Search

View Additional Section Content

AC-12-010: A 26 – Week, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants with Mild to Moderate Alzheimer’s Disease (AD), with an Optional 26 – Week Open-Label Extension.

For more information on this trial, click the link below.

https://clinicaltrials.gov/ct2/show/NCT01741194?term=nct01741194&rank=1

Clinical Trial Categories

  • Alzheimer's Disease
Contact
Jennifer McGowan at 215-327-0161

Location

  • Abington Neurological Associates, Ltd

Find a Physician
Search Our Directory

215-481-MEDI

Schedule a
Test

215-481-EXAM

Clinical Trials Details